Multiple sclerosis is an autoimmune disease of the central nervous system believed to be mediated by pathogenic T lymphocytes. We have developed a next-generation therapy in which cells secrete specific therapeutic molecules to silence these aberrant T cells. We have shown that fibroblasts, transduced to secrete a myelin basic proteinderived peptide, abrogate disease in the murine experimental autoimmune encephalomyelitis model of multiple sclerosis, which we hypothesized using a low-zone tolerance mechanism. To determine the efficacy (or not) of this therapy in humans, we must ensure that patients receive comparable doses of therapeutic peptide. To this end, we have used liquid chromatography coupled to tandem mass spectrometry to detect a tryptic peptide, derived from the secreted therapeutic product, at nanomolar concentrations. Success depended on growing the transduced fibroblasts in defined PC-1 medium in the presence of a cocktail of protease inhibitors.
Introduction
Multiple sclerosis is an autoimmune disease of the central nervous system believed to be mediated by pathogenic T lymphocytes. 1, 2 Current treatments often involve the injection of immunomodulatory molecules, but these have modest efficacy and significant side effects. 3, 4 We have developed a cell-based gene therapy approach in which we have successfully treated mice suffering from experimental autoimmune encephalomyelitis, an animal model for multiple sclerosis. 5 In our protocol, we deliver an antigen-specific signal that induces an anti-inflammatory response, which silences pathogenic T lymphocytes by an, as yet, undefined low-zone tolerance mechanism. 6 This signal is expressed by transduced fibroblasts and comprises a secreted peptide, the sequence of which is derived either from proteolipid protein (PLP 101-157) or myelin basic protein (MBP 71-111). 7 Our encouraging studies in mice have resulted in us preparing for a phase I clinical trial, in which multiple sclerosis patients receive therapeutic cells secreting peptide MBP 71-111, which are sequestered in devices placed subcutaneously. This strategy ensures that implants can be speedily removed should an adverse event occur, and also allows us to use allogeneic cells so that one universal transduced (diploid) cell line can be used for all patients.
To guarantee that patients receive comparable doses of therapeutic peptide, we must be able to measure the amount of the MBP-derived peptide secreted by therapeutic cells in vitro. In this paper, we describe preliminary work that shows the feasibility of using a mass spectrometry-based assay for this purpose.
Results
We used capillary liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS), because it is a very effective technology for detecting small amounts of a specific peptide in a complex biological matrix. 8 We have no way of knowing the exact form of the secreted MBP peptide, and it is larger (42 residues) than the ideal size range for a targeted LC-MS/MS assay. Consequently, we chose not to attempt to detect the intact secreted MBP peptide, but focused on the largest fragment resulting from trypsin digestion (MBP 82-93-TQDENPVVHFFK). This tryptic peptide is readily synthesized, has excellent electrospray MS sensitivity and yields a very characteristic fragment ion spectrum (Figure 1a) , making it easy to design a highly specific assay. In this instance, the mass spectrometer was programed to fragment all ions at the m/z value (730.86) of the 2+ charge state of the MBP tryptic peptide. By monitoring the intensity of two of the more intense fragment ions (m/z 873.5 and 1231.6), the peptide can be detected at subnanomolar concentrations in trypsindigested tissue culture medium (data not shown). The fragment ion at m/z 578.5 could also be used, but is subject to more interference from fragments from coeluting singly charged components in the mixture.
Although the MBP tryptic peptide is readily detected in digested tissue culture medium, attempts to detect the peptide in the supernatant of cultured transduced cells failed. It was hypothesized that enzymes secreted by the cells degraded the peptide, thereby preventing the accumulation of detectable amounts of product. Indeed, when the cell supernatant was spiked with the synthetic peptide and immediately processed for analysis, it was readily detected but not after the sample had been incubated for several hours (data not shown). The addition of a protease inhibitor cocktail allowed the MBP peptide to accumulate to detectable levels. Supernatants of transduced cells, harvested after 8 h of culture, trypsinized and analyzed by LC-MS/MS, contained peptide at concentrations below that of the sample containing medium spiked with 20 nM synthetic peptide, used as a positive control (Figure 2 ). The supernatant samples were analyzed after numerous blanks and negative controls; hence, there was no possibility that the observed signals were the result of instrument carryover. Even at these low levels, the quality of the MS/MS spectra is high (Figure 1b) . All of the major fragment ions in the MS/MS spectrum of the synthetic peptide standard are evident in the native sample, leaving no doubt that the peptide has been correctly identified. Cell supernatants harvested after 22 h yielded no detectable levels of MBP peptide, presumably because the protease inhibitors had been consumed and could no longer inhibit degradation of the secreted peptide. Mass spectra analyses of a therapeutic peptide JM Dadgari et al
Discussion
Until now, we have been unable to assess the amount of peptide product that transduced cells secrete, and have been confined to the use of northern blot analyses. Development of an enzyme-linked immunosorbent assay is problematic, as peptide-specific sera or monoclonal antibodies have notoriously low affinities and our MBP-derived products can be expected to have minimal tertiary structure. By using a targeted mass spectrometry-based assay, we can now measure the MBP peptide secreted from transduced fibroblasts, which is a crucial practical step in defining the dosage of peptide in vitro that will be administered to patients in a Food and Drug Administration-approved protocol for clinical trials. One critical factor in our success was to grow the transduced fibroblasts in defined (PC-1) medium, which, in fact, is preferable for a clinical trial. In earlier experiments, we used Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. We never detected any peptide product (either synthetic or secreted) in cell supernatants even using protein depletion kits, and we hypothesize that attempts to detect therapeutic peptide in vivo would be fruitless. Although the evidence for the secretion of the MBP peptide is incontrovertible, we have only a crude measure of the levels being produced. The LC-MS/MS assay will be made quantitative by using a stable isotope-labeled MBP tryptic peptide (TQDENPVVH[ 13 C 6 -F]FK) as an internal standard.
The ability to accurately measure levels of secreted peptide will allow us to define dosage in a phase I clinical trial for multiple sclerosis. The low concentration of therapeutic peptide secreted suggests that our therapy may indeed operate through a low-zone tolerance mechanism. 6 The application of LC-MS/MS to measure very small doses of a therapeutic peptide specifically targeted to the treatment of multiple sclerosis has potential use in combating other autoimmune diseases, the pathogenic T-cell epitopes of which have also been molecularly defined. 9 Such disorders include type I diabetes, rheumatoid arthritis and Graves' disease; therapies would involve secretion from encapsulated transduced cells of a measured amount of specific peptide encoding the appropriate T-cell epitope for each disease.
Materials and methods
The peptide MBP 82-93 was synthesized using FMOC-chemistry in the USC/Norris Cancer Center Microchemical Core Facility. A total of 3 Â 10 5 SJL/J fibroblast cells secreting murine MBP peptide 71-111 (SJL-KC-MBP) were grown in 10 ml PC-1 serum-free medium (Cambrex Bioscience, Walkersville, MD, USA) in a T-25 tissue culture flask (Falcon, Franklin Lakes, NJ, USA) at 37 1C and 5% CO 2 , and were allowed to reach B50% confluency after B24 h. The medium was removed and 5 ml filter-sterilized PC-1 medium, containing a cocktail of protease inhibitors (designated PC-1P), was added and the supernatant was harvested either at 8 or 22 h. This PC-1P medium comprised 250 mM Pefabloc SC Plus (Roche Applied Science, Mannheim, Germany), 75 mM leupeptin (Calbiochem, San Diego, CA, USA), 10 mM bestatin (Calbiochem) and 28 mM E-64 (Roche). Each supernatant was filtered through a 0.45 mM filter (Millipore, Billerica, MA, USA), and its protein concentration was determined using a bicinchoninic acid assay kit (Pierce, Rockford, IL, USA). Each experimental sample was comprised of 300 ml of supernatant, whereas for standard samples synthetic MBP peptide (82-93) was added to 300 ml PC-1 and PC-1P medium, to obtain a final concentration of 20 nM.
Each sample was lyophilized overnight in a sterile 15 ml centrifuge tube (Falcon), and was then resuspended at 0.5 mg ml À1 in 1 M ammonium bicarbonate (BioChemika Ultra, Sigma-Aldrich, Steinheim, Germany) in preparation for reduction, alkylation and digestion. Reagents for these steps were prepared using Milli-Q water (resistivity, o18.2 MO cm). After brief vortexing, 5 ml of the supernatant solution (2.5 mg) was added to 45 ml of 8 M urea in a nonautoclaved 0.6 ml microtube (Axygen Scientific Inc, Union City, CA). The 8 M urea solution had recently been deionized by passing it over a mixed-bed exchange resin IONAC NM-60 H + /OH À (JT Baker, Phillipsburg, NJ, USA). The proteins in the supernatant were then reduced for 15 min at 56 1C with 5 ml of 45 mM dithiothreitol (Pierce) and alkylated in the dark at room temperature for 15 min with 5 ml of 100 mM iodoacetamide (Pierce). The sample was diluted with 15 ml of 1 M ammonium bicarbonate and 125 ml Milli-Q water and digested overnight at 30 1C by adding 1 ml of trypsin solution comprising 100 ng ml Mass spectra analyses of a therapeutic peptide JM Dadgari et al
